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Type 2 diabetes mellitus is characterized by the deposition of islet amyloid polypeptide 
(IAPP) as amyloid in islets, a process thought to be toxic to β-cells. To determine the 
feasibility of targeting these aggregates therapeutically, we vaccinated transgenic (Tg) 
mice that overexpress human IAPP and were fed a high-fat diet to promote their diabetic 
phenotype. Our findings indicate that prophylactic vaccination with IAPP and its deriv-
ative IAPP7-19-TT, protects wild-type female mice, but not males, from obesity-induced 
early mortality, and the derivative showed a strong trend for prolonging the lifespan of 
Tg females but not males. Furthermore, IAPP7-19-TT-immunized Tg females cleared a glu-
cose bolus more efficiently than controls, while IAPP-immunized Tg females showed an 
impaired ability to clear a glucose bolus compared to their adjuvant injected Tg controls. 
Interestingly, IAPP or IAPP7-19-TT treatments had no effect on glucose clearance in Tg 
males. Overall, these beneficial effects of IAPP targeted immunization depend on Tg 
status, sex, and immunogen. Hence, future studies in this field should carefully consider 
these variables that clearly affect the therapeutic outcome. In conclusion, IAPP targeting 
immunotherapy may have benefits in patients with type 2 diabetes.
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inTrODUcTiOn
Insulin, produced by β-cells in the pancreas, has the key function of regulating blood glucose levels 
after food intake. In the early stages of type 2 diabetes, insulin production is normal or increased 
in absolute terms, but this is insufficient to control blood glucose levels due to reduced insulin 
sensitivity (1). Additionally, there may also be a deficit in the ability of the pancreas to secrete insulin 
to closely match the temporal rise in blood glucose levels, for example, immediately following a 
meal, resulting in hyperglycemia.
Islet amyloid polypeptide (IAPP or amylin) is also secreted by the β-cells (2). Its proposed 
functions include to inhibit insulin secretion (3) and glucagon secretion (4), although contradic-
tory findings have also been reported (5). IAPP can also aggregate and form amyloid deposits in 
the pancreas and, thus, is considered a pathological hallmark of type 2 diabetes (6). Post mortem 
studies indicate that between 40 and 90% of patients with type 2 diabetes show signs of amyloidosis, 
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and amyloid formation is a significant factor in the deterioration 
of islet function and reduction in β-cell mass [reviewed in (7)]. 
Interestingly, the process of IAPP deposition in the pancreas 
has been likened to amyloid-β (Aβ) deposition in the brain of 
Alzheimer’s disease patients.
With an increasing understanding of the complicated patho-
physiology seen in type 2 diabetes, treatment strategies aimed 
at achieving glycemic control need to be updated. A combina-
tion of dietary changes, exercise and prophylactic treatments 
to improve insulin sensitivity, preserve β-cell function, and 
promote weight loss has been articulated (8). While dietary 
changes and physical activity may reduce symptomatic burden, 
these measures generally do not reverse the pathogenesis of 
the  disease. Neither do available drugs that provide merely 
symptomatic relief. As IAPP aggregates are a prominent feature 
of type 2 diabetes that may be involved in its pathogenesis, 
targeting these for clearance is an attractive approach. This can 
potentially be accomplished with immunotherapy. Currently, 
the potential of using a vaccine to remove protein aggregates 
found in several neurodegenerative diseases is undergoing 
extensive research in in  vivo models of disease as well as in 
clinical trials. For example, immunotherapy targeting Aβ and 
tau deposits in the brain of Alzheimer’s disease patients, as 
well as α-synuclein deposits seen in Lewy Body disease or 
Parkinson’s disease, and against misfolded copper/zinc super-
oxide dismutase 1 protein in a mouse model of amyotrophic 
lateral sclerosis are at various stages of development [reviewed 
in (9)]. Thus, the idea of using immunotherapy to clear or 
prevent IAPP deposits seen in type 2 diabetes holds consider-
able promise as a therapeutic strategy.
In the current study, we investigated the feasibility of using an 
immunotherapeutic approach to target IAPP in a mouse model of 
type 2 diabetes. Our approach was to design an immunogen that 
contains the B-cell epitope of IAPP but is void of the hydrophobic 
region that confers fibrillogenicity and thereby toxicity under 
certain conditions. This is analogous to our approach targeting 
Aβ in Alzheimer’s disease (10–12). To promote antibody response 
toward such a shortened sequence, tetanus toxin fragment 
(TT947-967), T-helper epitope that is commonly used in various 
marketed vaccines was attached to the B-cell epitope of IAPP. 
We used an IAPP derivative (αα7-19 linked to tetanus toxin) or 
unmodified IAPP as vaccines to prophylactically (2–14 months) 
treat transgenic (Tg) mice that express human IAPP (hIAPP) in 
their pancreatic β-cells (13). About two-thirds of male hIAPP 
mice, but only 10% of female hIAPP Tg mice, have been reported 
to develop islet amyloid after 12–16 months on a high-fat diet 
(14). To assess the diabetic phenotype of the mice, their weights 
and plasma glucose levels were monitored at regular intervals. 
At the study endpoint, their ability to clear a glucose bolus was 
assessed as well as plasma insulin levels, followed by histological 
analysis of pancreatic tissue to determine if the vaccines cleared 
IAPP deposits and had any effect on total β-cell area. Wild-type 
(WT) mice were included as controls.
Our findings indicate that prophylactic vaccination with IAPP 
or its derivative, IAPP7-19-TT, reduces substantially death in WT 
female mice, with the derivative showing a strong trend for lower-
ing mortality in Tg females as well. The most significant benefits 
were observed when these two female groups were combined 
for analysis. In addition, sex and immunogen-specific effects 
were detected in Tg animals’ ability to clear the glucose bolus. 
Tg females immunized with the IAPP derivative had improved 
glucose clearance compared to controls. IAPP-immunized Tg 
females were impaired in their glucose clearance, which may be 




Human islet amyloid polypeptide Tg mice were obtained from 
VA Puget Sound Health Care System/University of Washington, 
Seattle, WA, USA. These mice, which have been extensively char-
acterized (13–16), were bred to obtain hemizygous hIAPP mice on 
a mixed DBA/2-C57Bl/6 background. F1 mice born from C57BL/6 
Tg male mice bred with DBA/2 non-Tg females were used in this 
study. The genotypes of the mice were confirmed by PCR of tail 
DNA with appropriate sense and antisense primers as previously 
reported (17). Non-Tg WT littermates were also used. All animal 
procedures were approved by the Institutional Animal Care and 
Use Committee (IACUC) at the New York University School of 
Medicine and were in accordance with the National Institutes of 
Health’s Guide for the Care and Use of Laboratory Animals.
To promote the deposition of hIAPP-derived islet amyloid, 
mice were maintained on a high-fat diet [Diet 12,290 (45% kcal 
fat, 35% kcal carbohydrates, 20% kcal protein); Research Diets] 
beginning at 2 months of age. They were maintained on a 12 h 
light/dark cycle in an AAALAC approved pathogen-free facility 
at the New York University School of Medicine and monitored 
daily by veterinary staff and/or the investigators. The animals 
were humanely euthanized at the end of the experimental 
period at 14  months with sodium pentobarbital (100  mg/kg, 
intraperitoneal (i.p.) and perfused trans-aortically with phos-
phate buffered saline (PBS) containing heparin. At this age, the 
animal should have developed substantial IAPP deposits in the 
pancreas. Animals that appeared to be sick and suffering during 
the experimental period were euthanized with the same dose of 
sodium pentobarbital (5 out of 251). Standard criteria used for 
early termination includes weight loss, inappetence, infection not 
responding to treatment and accompanied by systemic signs of 
illness, and signs of severe organ system dysfunction with poor 
prognosis as determined by veterinarian.
Vaccine Treatment
At 2 months of age, mice were bled and assigned for treatment 
with hIAPP derivative IAPP7-19-GPSL-Tetanus Toxin947-967 
(IAPP7-19-TT), full length hIAPP (IAPP) or control. Both peptides 
were synthesized at the W. M. Keck Foundation, Yale University 
(New Haven, CT, USA) by solid-phase technique and purified 
by high-performance liquid chromatography. The vaccines 
were administered in alum adjuvant (Adju-Phos®, Brenntag; 
overnight mixing at 4°C), which promotes primarily antibody 
production and has a lesser chance of eliciting T-cell-related side 
effects (18). The mice received an i.p. injection of 100 μg/100 μl 
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followed by a second injection 2 weeks later and then monthly 
thereafter until 14  months of age. Mice were killed when they 
were ~14–14.6 months old. Control mice received 100 μl alum 
adjuvant alone.
antibody response
Mice were bled prior to their first treatment and subsequently 
after every third injection until the study endpoint at 14 months 
of age. The antibody response to IAPP7-19-TT or IAPP was deter-
mined by a 1:200 dilution of plasma using ELISA, essentially as 
described previously (10, 11). The response was detected with 
goat anti-mouse IgG linked to horseradish peroxidase, 1:3000 
(Thermo), with tetramethyl benzidine (TMB) as the substrate.
Plasma iaPP levels
Islet amyloid polypeptide levels were measured from a random 
selection of the final bleeds using the human IAPP ELISA kit 
(EMD Millipore). Plasma samples were diluted and assayed as 
per the manufacturer’s instructions.
intraperitoneal glucose Tolerance Test
An i.p. glucose tolerance test (IPGTT) was carried out as 
described previously (15) with a few minor modifications. Mice 
were fasted for 16–18 h overnight and then anesthetized using 
sodium pentobarbital (50 mg/kg i.p.; Ovation Pharmaceuticals). 
The standard mouse anesthetic is not recommended as it affects 
glucose metabolism. After approximately 40  min, blood was 
drawn from the retro-orbital sinus to determine fasting plasma 
glucose levels. Thereafter, mice were injected i.p. with 10 μl/g 
body weight of 10% dextrose and blood was taken at 5, 15, 30, 
60, 90, and 120 min following commencement of the glucose 
bolus. The blood samples were used to determine plasma glu-
cose levels.
histology
One week following the IPGTT procedure, mice were again 
fasted overnight and sacrificed to obtain terminal plasma sam-
ples and tissue for analysis. Mice were anesthetized with sodium 
pentobarbital (100 mg/kg, i.p.) and perfused trans-aortically with 
PBS containing heparin. The pancreas was excised and split in 
half: one portion was frozen and stored at −80°C for biochemi-
cal assays and the other immersion-fixed in periodate-lysine-
paraformaldehyde buffer (PLP) and subsequently embedded in 
paraffin. From the embedded portion, 5 μm sections were cut and 
sections at 100 μm intervals were first deparaffinized in xylene 
and then stained with: (1) 0.5% thioflavin S (filtered), (2) anti-
IAPP 1:200 (Peninsula Labs, CA, USA) in polyclonal diluent (2% 
Triton-X, 0.1% sodium azide, 0.01% bacitracin, 2% bovine serum 
albumin, 10% normal serum in PBS pH 7.4), and (3) anti-insulin 
1:1000 (Sigma) in monoclonal diluent (MOM kit, Vector Labs, 
CA, USA). Prior to IAPP and insulin staining, antigen retrieval 
was carried out by boiling the sections in 0.2% citrate buffer for 
10 min (IAPP) or dipping them for the same amount of time into 
40% formic acid (insulin). The immunostained sections were 
revealed with 0.3% hydrogen peroxide in 3,3-diaminobenzidine 
tetrahydrochloride with nickel ammonium sulfate intensification. 
Slides were re-hydrated and dehydrated and coverslipped for 
analysis. The selection of tissue for analyses was completely 
unbiased and based on a random sampling from the excised half 
portion of fixed pancreas. The prevalence and severity of amyloid 
in this model has been found to be uniform throughout the 
pancreas (19).
Biochemical assays
Blood samples were collected at various time points during the 
course of vaccine or control adjuvant treatment and also at the 
terminal endpoint 1 week following the IPGTT procedure. Mice 
were fasted overnight and sacrificed to obtain terminal blood 
samples. Plasma glucose was measured using a glucose meter and 
glucose strips (Accu-Chek Active®, Roche).
Plasma samples obtained from the IPGTT bleeds were also 
used to determine plasma insulin levels by ELISA using a commer-
cially available kit [Insulin (Mouse) High and Low Range ELISA, 
ALPCO Diagnostics, NH]. Plasma glucose levels were measured 
from fed mice during the course of vaccine or adjuvant treatment, 
and from fasted mice during the IPGTT measurements.
image analysis
Images were acquired with a Leica DM5000B microscope and 
MBF Bioscience software. Images were then merged with 
Photoshop (Adobe) to obtain a composite image of the entire 
tissue section. The area of pancreas (islet) staining was quanti-
fied with NIH Image J software. The percentage of the total 
area stained for IAPP or insulin was calculated as total IAPP or 
insulin positive area (square micrometer), i.e., area occupied by 
the reaction product, divided by the total section area (square 
micrometer) and expressed as percentages. Amyloid deposits 
were detected with Thioflavin S and the percentage of positive 
islet area calculated. Islets that were not Thioflavin S positive 
could be easily identified on these sections.
statistical analysis
Data analysis was done with Graph Pad Prism 5 (GraphPad 
Software, Inc., La Jolla, CA) and StatSoft Statistica 6 (StatSoft, 
Inc., Tulsa, OK) software. Mice were analyzed based on treat-
ment, sex, and genotype, for example, control female Tg mice 
versus IAPP7-19-TT-treated female Tg mice. Kaplan–Meier 
survival graphs were plotted for all mice till the time of IPGTT. 
Survival curves were compared using Mantel–Cox (log-rank) 
test and median survival was only reported when survival was 
below 50%. Plasma glucose, fasting plasma glucose, and IPGTT 
plasma glucose levels were analyzed by two-way ANOVA, 
repeated measures and Newman–Keuls post  hoc test. Plasma 
insulin and histological analysis of insulin, IAPP, and Thioflavin 
S immunoreactivity of vaccinated versus control adjuvant treated 
groups was analyzed by one-way ANOVA. When the data failed 
at least two of three normality tests (Kolmogorov–Smirnov, 
D’Agostino and Pearson omnibus, and Shapiro–Wilk normality 
tests), non-parametric Kruskal–Wallis test was used. The test 
was two-tailed as the levels could be expected to be increased or 
decreased. Data are expressed as mean ± SEM. A p ≤ 0.05 was 
considered significant.
TaBle 1 | Mice enrolled and mouse deaths during the prophylactic iaPP7-19-TT study.























Control 53 18 13 10 12 20 5 6 3 6 29 4
IAPP7-19-tt 61 23 17 13 8 36 12 9 9 6 17 8
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resUlTs
survival – iaPP7-19-TT study
Table  1 shows the numbers of mice of different sex and 
genetic background that were enrolled and died in the prophy-
lactic IAPP7-19-TT experiment starting at 2–3 months of age. Mice 
received monthly injections of IAPP7-19-TT, a derivative of IAPP in 
alum adjuvant or adjuvant alone. A number of mice did not survive 
until the study endpoint and died during the 12-month course of 
the study (Table 1). As both WT and Tg mice died prematurely, 
it was unrelated to overexpression of hIAPP but was likely related 
to their obesity. Kaplan–Meier analyses of Tg and WT littermate 
mouse deaths during prophylactic IAPP7-19-TT or control treatment 
was carried out. Analysis of the survival curves indicated that the 
IAPP7-19-TT-treated Tg female mice trended strongly to survive 
longer than control (adjuvant alone) Tg female mice (p = 0.056), 
with a hazard ratio of 2.5, i.e., two and a half times less likely to die 
than controls (Figure 1A). Significantly more IAPP7-19-TT-treated 
WT female mice survived till the study endpoint than control 
treated mice (84.6% versus 30%, p = 0.02), and had a fivefold less 
chance of dying, hazard ratio = 5.11 (Figure 1B). Combining Tg 
and WT female mice showed that a significantly higher propor-
tion of the IAPP7-19-TT-treated mice survived till the end of the 
study than control treated mice (75% versus 35.7%, p = 0.002) 
with a hazard ratio of 3.4 (Figure 1C). Considering these robust 
differences in survival, it is important to note that the surviving 
animals may not accurately represent the original group.
There were no significant differences in the survival propor-
tions of IAPP7-19-TT or control-treated Tg or WT male mice 
(Figures 1D–F) although both treated groups showed a trend for 
improved survival compared to their controls.
Further analysis of the weight data showed a similar slope of 
weight gain in mice that died during the study compared to mice 
that survived until the end of the study (data not shown), suggest-
ing that increased mortality could not be explained by abnormal 
weight gain and related complications or by weight loss because 
of disease in the colony.
Weight – iaPP7-19-TT study
To induce a diabetic phenotype, all the mice enrolled in the study 
were fed a high-fat diet from 2 months of age till the terminal end 
point. There were no significant differences in the weights of the 
groups (Figure S1 in Supplementary Material).
antibody response and Plasma iaPP 
levels – iaPP7-19-TT study
The antibody response toward the IAPP7-19-TT immunogen was 
robust and comparable between sexes and the various treated 
groups (Tg and WT). IgG levels were higher than IgM levels. 
As expected, these antibodies showed a more modest reactivity 
toward IAPP (Figure 2).
Random sampling of Tfinal plasma samples from the study 
revealed increased plasma IAPP levels in immunized mice 
(WT: 466 (average) ± 109 (SEM) pmol/l, n = 13; Tg: 2093 ± 429, 
n =  19) compared to control mice (WT: 22 ±  5, n =  7; Tg: 
149 ± 104, n = 9), indicating target engagement of the antibodies 
generated toward the vaccine. Sex differences were not appar-
ent and plasma IAPP levels from Tg mice that had died during 
the course of the study (T3–T4) also had a comparable increase 
(Tg immunized: 950 ± 421, n = 6; Tg control: 134 ± 3, n = 7).
glucose levels – iaPP7-19-TT study
Measurements of plasma glucose levels during the course of 
treatment (12 months) showed a significant decrease in plasma 
glucose levels prior to terminal sacrifice (T0–T4) for Tg female 
(p  =  0.003), and male mice (p  =  0.004; Figures S2A,C in 
Supplementary Material). However, glucose levels did not differ 
between control and treated Tg groups and there was not an 
interaction between the two factors (bleeds and treatment). 
Plasma glucose also decreased significantly over the course of 
the five bleeds (T0–T4) within WT female (p  =  0.001) and 
WT male mice (p <  0.0001; Figures S2B,D in Supplementary 
Material). Again, there were no differences between the 
 treatment groups or an interaction between the two factors 
(treatment and bleeds).
As the glucose tolerance test was performed between bleeds 
T4 and Tfinal, it may potentially influence Tfinal levels. Hence, 
terminal bleed plasma glucose levels were analyzed separately 
from T0 to T4. No treatment effect was observed in plasma glu-
cose levels from the terminal bleed (Figure S2E in Supplementary 
Material).
Based on these measurements, the mice are not developing 
a severe diabetic phenotype, in spite of being fed a high-fat diet 
and gaining weight during the course of the study. Hence, it may 
be difficult to assess treatment effect based on this parameter. 
The glucose tolerance test is more appropriate to detect subtle 
differences in diabetic phenotype.
glucose Tolerance Test – iaPP7-19-TT study
To assess their diabetic status, 1  week prior to the end of the 
study period, mice were fasted for 16  h and then underwent 
an IPGTT. The test clearly worked as it was supposed to as 
evident by highly significant differences in glucose levels with 
time (p < 0.0001) in all groups analyzed (Figures 3A–D). Data 
were also analyzed as area under the curve (AUC) but it did not 
provide additional insight.
FigUre 1 | Prophylactic iaPP7-19-TT vaccination promotes survival in Tg and WT female mice. Kaplan–Meier survival plots for mice enrolled in the 
prophylactic IAPP7-19-TT study. (a–c) Tg and WT female mice receiving IAPP7-19-TT treatment had a better survival outcome than their control adjuvant treated 
counterparts (p = 0.056 (Mantel–Cox test) for Tg mice, p = 0.02 for WT mice, and p = 0.002 for combined Tg and WT mice). (D–F) Prophylactic IAPP7-19-TT 
treatment did not significantly improve survival of Tg or WT male mice.
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Females
The IAPP7-19-TT treated Tg mice appeared to clear the glucose 
bolus more efficiently than the Tg controls, as was anticipated. 
Although a significant treatment effect was not observed in the 
Tg mice (p = 0.15), a significant interaction between time and 
treatment was detected (p = 0.002, Figure 3A). These findings 
indicate that clearance of the glucose bolus over time differed 
between the Tg treated and control mice. The WT IAPP7-19-TT 
treated and controls did not differ significantly in glucose 
clearance, although plasma glucose levels remained elevated 
for the control-treated mice and did not return to basal levels 
as for the IAPP7-19-TT-treated mice (Figure  3B). Both Tg and 
WT control mice trended to being less efficient at clearing 
the glucose bolus than their IAPP7-19-TT-treated counterparts 
(Figures  3A,B), indicating that IAPP7-19-TT treatment was 
attenuating the diabetic phenotype.
Males
There was a trend for the IAPP7-19-TT-treated Tg (treatment 
effect: p =  0.08) to clear the glucose bolus less efficiently than 
their controls, but not for WT (p = 0.11). This was also reflected 
within the Tg animals in differences in glucose clearance over 
time between the treatment groups (treatment ×  time interac-
tion: p  =  0.05; Figures  3C,D). IAPP7-19-TT-treated Tg mice 
showed a trend (p = 0.08), and IAPP7-19-TT-treated WT mice had 
significantly higher plasma glucose levels (p =  0.05) compared 
FigUre 2 | iaPP7-19-TT is highly immunogenic in mice but elicits a modest antibody response toward iaPP. Tg and WT mice were immunized from 
2 months of age with alum adjuvant (Control) or IAPP7-19-TT peptide in alum adjuvant (IAPP7-19-TT). Mice were bled at regular intervals (T0–TF) and plasma samples 
(1:200) from the animals were analyzed by ELISA. IAPP7-19-TT-treated mice developed a strong and sustained IgG immune response to the immunogen (a,e) and a 
more modest response to IAPP (B,F). IgG levels (a,B,e,F) were higher than IgM levels (c,D,g,h). Error bars indicate SEM.
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FigUre 3 | Prophylactic iaPP7-19-TT treatment attenuates glucose clearance in female Tg and WT mice. At approximately 14 months of age, the diabetic 
status of the mice was assessed by the intraperitoneal glucose tolerance test (IPGTT). Mice were starved overnight and then bled to determine fasting plasma 
glucose levels (T0). They received a glucose bolus and were bled at various time points until T120 min. (a,B) IAPP7-19-TT-treated female Tg and WT mice trended to 
be able to clear the glucose bolus faster than control mice. (c,D) IAPP7-19-TT-treated male Tg or WT mice trended to clear the glucose bolus less efficiently than their 
controls. Error bars indicate SEM. Note that the increase in average values in the control group at 120 min in (a) is because one mouse, with a substantial drop in 
glucose levels at 90 min, died before the 120-min time point. A biphasic response was not seen in any of mice that went through this test, indicating that the 
procedure was performed correctly. Such errors can occur when the glucose is injected into the intestines instead of entering the peritoneal cavity.
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to control-treated mice (data not shown). These results were 
contrary to what we had anticipated if the treatment was attenuat-
ing a diabetic phenotype. The Tg controls did not show any sig-
nificant differences in glucose levels when compared to their WT 
counterparts, which suggests a lack of diabetic phenotype in these 
male Tg mice. Hence, these effects may reflect immunization-
mediated clearance of IAPP and, therefore, lessened ability to 
regulate spikes in glucose levels.
insulin levels – iaPP7-19-TT study
Plasma insulin levels from the terminal bleeds were 
not   significantly  changed in the Tg or WT controls versus 
IAPP7-19-TT-immunized mice. There were no significant differ-
ences either between these groups when separated by sex (Figure 
S3 in Supplementary Material).
histology – iaPP7-19-TT study
To obtain information about relative β-cell area in these animals, 
insulin and IAPP immunostaining was performed on Tg female 
and male mice (Figures  4A,B). The treatment groups did not 
differ within each sex.
Thioflavin S staining indicated that amyloid burden was very 
variable between controls and IAPP7-19-TT-immunized mice, and 
there were no significant differences between these groups for 
either sex (Figure 4C). Representative images show serial pan-
creatic tissue sections from an IAPP7-19-TT-treated Tg mouse with 
islet IAPP and insulin staining as well as some amyloid deposits 
stained with Thioflavin S (Figure 4D).
Pancreas sections from WT female and male-treated and 
control mice were also immunostained for insulin immunore-
activity to assess relative β-cell area in these animals. Analysis 
of the sections indicated no significant differences in β-cell area 
staining between control and treated groups within each sex (data 
not shown).
survival – iaPP study
Table  2 shows the numbers of mice of different sex and genetic 
background that were enrolled in the prophylactic IAPP vaccine 
study starting at 2–3 months of age. The experimental design was the 
same as in the IAPP7-19-TT study. As in that study, a number of mice 
did not survive until the study endpoint (Table 2). Kaplan–Meier 
analyses of Tg and WT mouse deaths during prophylactic IAPP 
or control treatment was carried out (Figures 5A–F). Analysis of 
the survival curves prior to the glucose tolerance test or terminal 
sacrifice at 14 months of age indicated that a significantly greater 
proportion of WT female mice receiving the IAPP vaccine had 
FigUre 4 | relative pancreatic β-cell area or amyloid burden are not changed in iaPP7-19-TT-immunized Tg mice versus controls. Pancreatic tissue was 
collected at the study endpoint and used for histological analysis of insulin, IAPP, and amyloid load as determined by thioflavin S staining. (a–c) Relative islet β-cell 
area and amyloid burden were not altered in treated mice versus controls. Error bars indicate SEM. (D) Representative immunostaining of pancreatic tissue from a Tg 
mouse with some Thioflavin S positive IAPP deposits in the islets. Pancreatic tissue was sectioned and immunostained with anti-IAPP and insulin antibodies and 
processed for thioflavin S staining. Large arrows point at four islets of different sizes. The narrow arrow points at Thioflavin S positive deposit within one of the islets. 
Scale bar = 250 μm.
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FigUre 5 | Prophylactic iaPP vaccination promotes survival in WT female mice. Kaplan–Meier survival plots for mice enrolled in the prophylactic IAPP study. 
(a,c,D–F) Tg female and male and WT male mice receiving IAPP treatment, as well as combined Tg and WT groups within each sex, had the same survival 
outcome as their control adjuvant-treated counterparts. (B) However, female WT IAPP-treated mice had a significantly better survival rate than WT control treated 
mice (p = 0.004).
TaBle 2 | Mice enrolled and mouse deaths during the prophylactic iaPP study.
























Control 59 16 17 9 17 26 11 6 1 8 25 5 3
IAPP 78 24 28 12 14 44 14 14 7 9 27 5 2
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survived till the study end point compared to WT female control-
treated mice (p = 0.004, Figure 5B). As only one out of nine WT 
control females survived, a hazard ratio could not be calculated. 
Tg female and male mice and WT male mice receiving control or 
IAPP treatment, as well as combined Tg and WT groups within 
each sex, did not show any significant differences in their survival 
proportions during the course of the study (Figures 5A,C,D–F).
As in the IAPP7-19TT study, further analysis of the weight 
data showed a similar slope of weight gain in mice that died 
during the study compared to mice that survived until the 
end of the study (data not shown), suggesting that increased 
mortality could not be explained by abnormal weight gain and 
related complications or by weight loss because of disease in 
the colony.
FigUre 6 | The iaPP peptide is highly immunogenic in mice. (a–D) Tg and WT mice were immunized from 2 months of age with alum adjuvant (Control) or 
IAPP peptide in alum adjuvant (IAPP). Mice were bled at regular intervals (T0–TF) and plasma samples (1:200) from the animals were analyzed by ELISA. 
IAPP-treated mice developed a strong and sustained immune response to the IAPP immunogen. (a,c) IgG levels were higher than (B,D) IgM levels. Error bars 
indicate SEM.
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Weight – iaPP study
To induce a diabetic phenotype, all the mice enrolled in the study 
were fed a high-fat diet from 2 months of age till the terminal 
endpoint. There were no significant differences in the weights of 
the groups (Figure S4 in Supplementary Material).
antibody response and Plasma iaPP 
levels – iaPP study
As expected, the antibody response toward the IAPP immunogen 
was stronger than toward this peptide in the IAPP7-19-TT study as 
antibodies can be generated against the whole peptide (Figure 6). 
In the IAPP7-19-TT study, a subpopulation of the antibodies is gen-
erated against the TT helper epitope resulting in a strong overall 
response against the immunogen, of which only some of the 
antibodies will recognize the 7-19 IAPP epitopes.
Random sampling of plasma samples from the study revealed 
increased plasma IAPP levels in immunized mice (WT: 514 
(average) ±  214 (SEM) pmol/l, n =  7; Tg: 494 ±  370, n =  13) 
compared to control mice (WT: 12 ±  1, n =  4; Tg: 120 ±  92, 
n = 14), indicating target engagement of the antibodies generated 
toward the vaccine.
glucose levels – iaPP study
Measurements of plasma glucose levels during the course of 
treatment (12 months) showed that glucose levels decreased with 
time for female and male Tg mice (p < 0.0001) and male WT 
mice (p < 0.0001; Figure S5 in Supplementary Material). There 
were no differences in glucose levels over time in WT females 
(p = 0.26). Also, there were no significant differences between 
controls and IAPP immunized mice within each of these four 
groups. Neither was there an interaction between the two factors 
(bleeds versus treatment). Tfinal plasma glucose levels for IAPP-
immunized mice were significantly greater than those in control 
mice for female Tg mice (p = 0.03; Figure S5). No treatment effect 
was observed on blood glucose levels from the terminal bleed 
FigUre 7 | Prophylactic iaPP treatment does not affect glucose clearance in Tg or WT mice. At approximately 14 months of age, the diabetic status of the 
mice was assessed by the intraperitoneal glucose tolerance test (IPGTT). Mice were starved overnight and then bled to determine fasting plasma glucose levels (T0). 
They received a glucose bolus and were bled at various time points until T120 min. (a–D) IAPP immunized Tg females (a) were less able to regulate glucose levels 
than controls. The other groups (B–D) did not differ significantly. Error bars indicate SEM.
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in the other groups. This may suggest detrimental effects of the 
immunization in female Tg mice but as the mice are not develop-
ing a robust diabetic phenotype (rising blood glucose levels), it is 
difficult to interpret this finding. IAPP may have a role in glycemic 
regulation and could potentially prevent spikes in glucose levels 
after meals (3–5, 20). The immunization may enhance clearance 
of IAPP, which may result in increased glucose levels. Overall, as 
for the IAPP7-19-TT study, based on these measurements, the mice 
are not developing a severe diabetic phenotype, in spite of being 
fed a high-fat diet and gaining weight during the course of the 
study. Hence, it may be difficult to assess treatment effect based 
on this parameter. The glucose tolerance test is more appropriate 
to detect subtle differences in diabetic phenotype.
glucose Tolerance Test – iaPP study
One week prior to the end of the study period, mice underwent 
the IPGTT in the same manner as in the IAPP7-19-TT study. Plasma 
glucose measurements were recorded prior to and at regular 
intervals up to 2 h post-delivery of the glucose bolus.
Females
The test worked as expected as evidenced by the highly significant 
difference in glucose levels with time (p < 0.0001) in the Tg mice. 
IAPP-immunized Tg mice returned to basal plasma glucose levels 
significantly more slowly than control mice (treatment effect: 
p = 0.03; treatment ×  time interaction: p = 0.013, Figure 7A). 
This would suggest that IAPP immunized Tg females were less 
able to regulate glucose levels. Since only one female control WT 
mouse survived till the IPGTT test (Table 2; Figure 7B), statisti-
cal analysis of the results for WT female mice is excluded.
Males
Here too the test worked as expected as evidenced by the highly 
significant difference in glucose levels with time (p < 0.0001) in 
both the Tg and WT mice. In contrast to the females, Tg male 
IAPP immunized mice appeared to clear the glucose bolus 
more efficiently than Tg male controls. However, there was no 
significant treatment effect on plasma glucose levels (p = 0.153; 
Figure  7C). The WT immunized and controls did not differ 
significantly either (Figure 7D). Data were also analyzed as AUC 
but it did not provide further clarification.
insulin levels – iaPP study
Plasma insulin levels from the terminal bleeds were not signifi-
cantly changed in the Tg or WT controls versus IAPP immunized 
mice (Figure S6 in Supplementary Material). Separating for sex, 
there were no significant differences either between these groups.
histology – iaPP study
Insulin and IAPP immunostaining was performed on the Tg 
mice. There were no significant differences in the total area of 
FigUre 8 | relative pancreatic β-cell area or amyloid burden are not 
changed in iaPP immunized Tg mice versus controls. Pancreatic tissue 
was collected at the study endpoint and used for histological analysis of 
insulin, IAPP and amyloid load as determined by thioflavin S staining. (a–c) 
Relative islet β-cell area and amyloid burden were not altered in treated 
versus control mice. Error bars indicate SEM.
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insulin or IAPP staining between control and treated groups 
within each sex (Figures 8A,B).
As with islet area, there were no significant differences in 
amyloid burden between controls and IAPP immunized mice for 
either sex (Figure 8C). Insulin immunostaining of WT mice also 
showed no differences in islet area between control and treated 
groups within each sex (data not shown).
DiscUssiOn
Islet amyloid polypeptide is co-secreted from pancreatic β-cells 
with insulin and converted to amyloid deposits in type 2 diabetes 
[reviewed in (21)]. The exact physiological function of IAPP is 
unknown, but it is thought to play a role in glucose homeostasis 
[reviewed in (22)]. The pathogenicity of islet amyloid aggregates 
has also been demonstrated. Insoluble IAPP fibrils were shown 
to be toxic to pancreatic islet cells (23), as were soluble oligomers 
(24), with both resulting in apoptotic β-cell death. Therefore, 
it has been suggested that islet amyloid may be an important 
link between insulin resistance and β-cell dysfunction in type 
2 diabetes (25, 26). More recently, the focus has shifted to the 
role of IAPP oligomers in disease pathophysiology [reviewed in 
(7, 27)]. Thus, based on the current consensus, the aim of our 
study was to determine if immunotherapy targeting IAPP could 
be used as a novel treatment strategy to prevent fibrillogenesis of 
and/or remove IAPP aggregates and improve glucose regulation 
in type 2 diabetes.
Lin and colleagues had previously used a vaccination approach 
with “Alzheimer’s Aβ1-40 oligomers,” as the immunogen, to elicit 
the generation of anti-toxic oligomer antibodies and determine if 
IAPP deposits are formed intra- or extracellularly. Additionally, 
they hoped to prevent pancreatic β-cell loss (24). They showed 
that in two IAPP Tg mouse models, IAPP oligomers were 
detected intracellularly, and one of their models had extracellular 
IAPP amyloid deposits but vaccination with their immunogen 
had somewhat detrimental rather than protective effects (24). 
It is conceivable that their oligomeric immunogen may have 
had direct toxic effects on β-cells. Our approach was to design 
an immunogen that contains the B-cell epitope of IAPP but is 
void of the hydrophobic region that confers fibrillogenicity and 
thereby toxicity under certain conditions. This is analogous to 
our approach targeting Aβ in Alzheimer’s disease (10–12). To 
promote antibody response toward such a shortened sequence, 
tetanus toxin fragment (TT947-967) T-helper epitope that is com-
monly used in various marketed vaccines was attached to the 
B-cell epitope of IAPP.
The major benefit of our prophylactic IAPP7-19-TT and 
IAPP vaccinations was prolonged lifespan of the WT female 
mice, importantly in two independent studies (p =  0.02 and 
p = 0.004), with the IAPP7-19-TT immunization showing as well 
a strong trend (p = 0.056) for improved survival of Tg female 
mice. Indeed, the most significant effect on survival was 
observed when the Tg and WT female groups within that study 
were combined (p = 0.002). Hence, the surviving controls may 
not truly represent the group. It should be noted that all the 
mice were obese, having been on the high-fat diet throughout 
the study, and showed an increased rate of mortality compared 
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compared to mice that survived until the end of the study, indicat-
ing that increased mortality could not be explained by abnormal 
weight gain and related complications or by weight loss because 
of disease in the colony. The mice were housed in a pathogen-free 
facility, in which each cage has a separate air filtration built into 
the cage carts. Furthermore, controls and vaccinated mice were 
housed together, and the vaccination, in particular with the IAPP 
derivative, reduced mortality. Likewise, increased mortality can-
not be explained by the adjuvant as both controls and vaccinated 
mice received the same amount of it and at the same intervals. We 
have used the same alum adjuvant in multiple studies in various 
Alzheimer’s models mice without obvious side effects (12, 35, 
36). This type of adjuvant is approved for human use because of 
its safety. Additionally, repeated i.p. injections did not appear to 
result in peritonitis. We have used the same repeated i.p. injec-
tion approach in other studies using various mouse models on a 
regular diet without increased mortality (36, 37).
The second most significant benefit in the prophylactic stud-
ies was improved glucose clearance in IAPP7-19-TT-immunized Tg 
females, which interestingly was not observed in Tg males or WT 
mice. By carrying out the IPGTT, we were able to observe more 
subtle differences in the diabetic status of the mice. The most 
obvious explanation for these sex and model differences is that 
the Tg females appear to have more of a diabetic phenotype based 
on higher peak glucose values in the IPGTT assay, compared to 
identical males or WT mice.
Opposite effects on glucose clearance were observed in 
females receiving the IAPP vaccine. The beneficial effect of the 
immunization on glucose regulation in the Tg females in the 
IAPP7-19-TT study and detrimental effects on the females in the 
IAPP study may be related to differences in antibody response. In 
the IAPP7-19-TT group, modest antibody response was generated 
against IAPP that may be sufficient to clear soluble toxic IAPP 
aggregates while having minimal effect on normal IAPP that is 
needed for glycemic regulation [(38), and reviewed in (20)]. By 
contrast, in the IAPP group, moderate-to-high antibody response 
was generated against IAPP, which may reduce normal IAPP levels 
too much and thereby have adverse effects on glucose regulation. 
In support of this scenario, IAPP-deficient mice have been shown 
to develop a more severe form of alloxan-induced diabetes (39). 
This important finding suggests that in future clinical trials, care 
should be taken not to induce a robust immune response against 
IAPP that may have adverse effects on glucose regulation by 
interfering with the physiological role of IAPP. As this may prove 
difficult in individual subjects, passive immunization with IAPP 
targeting antibodies may be preferable.
In contrast to the females, the IPGTT for male mice in the 
studies did not indicate any differences between the two vaccines, 
IAPP7-19-TT or IAPP, and their controls. It is not entirely clear why 
the immunotherapy was beneficial in the females and not in the 
males. One possibility is that it may be indirectly related to less 
amyloid burden in the females. The development of pancreatic 
IAPP amyloid deposits may actually be a way to sequester and con-
tain in a relatively inert form more toxic smaller IAPP aggregates. 
As the females have less amyloid burden, they may have more of 
these smaller IAPP aggregates that may induce β-cell impairment 
and a diabetic phenotype as reflected in higher glucose levels in 
to normal mice. To clarify why survival of WT female mice is 
extended with both vaccines, whereas apparently only with one 
of the vaccines in Tg females, will require additional studies 
in younger control mice to assess benefits prior to extensive 
mortality.
Due to the high mortality rates observed during the course 
of the study, we enrolled a total of 251 mice in the two studies 
(114 and 137, respectively), more than in any other report of 
this model. This large number of mice is likely more than in any 
hIAPP model report and most Tg mouse studies have much fewer 
mice. For example, Wang et al. used 15 hIAPP and 9 WT mice in 
their study (19), Hull et al. (15) used 48 hIAPP mice, and Zraika 
et al. (28) report on six mice per group. However, it would have 
been preferable to have had more mice in some of the groups for 
the endpoint measures.
The high mortality was seen both in Tg and WT mice and 
is, therefore, not related to the transgene. It can be explained by 
the long-term high-fat diet. Such high-fat diet induced mortality 
has been described in numerous studies. For example, Baur et al. 
(29) showed that resveratrol improved survival of mice on a 
high-fat diet. In that particular study, WT mice received high-fat 
diet from 50 weeks of age until 115 weeks of age with only about 
40% of the mice surviving. We saw a similar percentage survival 
(about 30–50%) when the mice started on the diet at a young 
age (2 months) and stayed on it until 15–16 months of age. An 
example of other publications reporting similar reduced survival 
on a high-fat diet includes a study by Zhang et al. (30), who 
demonstrated that female WT mice fed a high-fat diet from 
8 months of age had about 60% survival rate at 2 years, compared 
to control WT mice with about 90% survival rate. Another recent 
study from Baker et al. (31) described that WT mice on a 9% 
fat diet had a significantly reduced median lifespan (673 days) 
compared to mice on a 5% fat diet (897 days). An example from 
a disease model includes a study describing the effect of diet on 
TRAMP prostate cancer Tg mice fed from 4 to 50 weeks of age 
(32). In that particular report, control diet mice had a survival 
rate of 55%, but high-fat diet fed mice had only a 21% survival 
rate. There are other publications in which various Tg models 
have been fed a high-fat diet but for shorter periods of time, 
which precludes measuring survival rates. Examples of sex dif-
ferences include a publication by Everitt et al. (33) showing high 
mortality in WT females (48%) receiving high-fat diet but not in 
males of a strain that is prone to develop myocardial disease, in 
females in particular. Additionally, in a non-mammalian model, 
Sun et al. (34) showed that a high-fat diet reduced the lifespan 
of female drosophila compared to males. While we saw reduced 
survival in both females and males on a high-fat diet, the effect 
was more pronounced in the females.
It is well established that high-fat diet promotes cardiovascular 
disease that may explain the enhanced mortality in the WT and 
Tg control groups. The beneficial effects of IAPP vaccination on 
survival are particularly strong in the females and need to be 
clarified in future studies.
We can rule out disease in the colony as a contributing factor as 
increased mortality was only seen in mice on high-fat diet and not 
in all groups and only some mice in each cage died. A similar slope 
of weight gain was observed in mice that died during the study, 
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the females following a glucose bolus. The antibodies generated in 
response to the vaccination are likely to have better access to these 
smaller aggregates than the large amyloid deposits, and may, there-
fore, show beneficial effects in the females and not in the males.
In spite of the antibody response in the immunized mice and 
target engagement as evidenced by the related increase in plasma 
IAPP, several parameters were not affected by the immuniza-
tions, which may be explained by the relatively modest diabetic 
phenotype of this model. All the mice continued to gain weight 
as expected, since they were fed a high-fat diet. However, glucose 
levels were variable. In both studies, glucose levels decreased 
significantly over the time course of the study both in Tg and 
WT mice. This finding has also been reported by others in a 
large study of female C57BL/J6 mice fed a high-fat diet, in which 
circulating glucose levels declined throughout the 12-month 
study, although insulin levels did progressively increase (40). The 
reduction in glucose levels we observed may suggest that the mice 
are not developing a robust diabetic phenotype. It was, therefore, 
not surprising that the immunotherapy did generally not affect 
baseline glucose levels. An exception to this was observed in 
Tg females immunized with IAPP that had significantly higher 
resting glucose levels at sacrifice than identical controls. This 
increase was only observed at this time point and may relate to 
their impaired ability to clear a glucose bolus compared to their 
non-immunized controls.
Besides resting glucose levels, other markers of severe diabetes 
did not differ between treated and control mice, likely because 
this model does not have severe diabetes. Plasma insulin levels 
were only assessed from the final bleed at terminal sacrifice and 
were not altered in any of the mice tested. Relative β-cell area in 
the Tg mice, determined by staining for insulin and IAPP, showed 
no changes in female or male Tg mice receiving the prophylactic 
IAPP7-19-TT or IAPP treatment, compared to controls. This was 
also the case with amyloid load. Overall, our findings indicate 
beneficial effects of IAPP-targeted immunization. The benefits 
depend on Tg status, sex, and immunogen. Considering these 
differences, it is advisable in future studies to pay close attention 
to these variables that clearly affect the therapeutic outcome. Our 
results are in contrast with a prior study that showed detrimental 
effects of immunization with a different immunogen in different 
models of type 2 diabetes (24). In conclusion, IAPP targeting 
immunotherapy may have benefits in humans suffering from 
type 2 diabetes. Further studies are warranted to investigate in 
more detail the mechanism by which such immunotherapy can 
promote survival, and improve glucose clearance.
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